Navigation Links
Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has signed an exclusive agreement with WILEX AG for commercialization rights in the United States for RENCAREX® (girentuximab).  RENCAREX® is a Phase III product candidate for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC).

Under the terms of the agreement, WILEX will receive $19.0 million upfront payments and development fees plus milestone payments and royalties on U.S. net sales of RENCAREX®.  In addition, Prometheus will co-fund a portion of the ongoing development of RENCAREX®. The deal terms also include an agreement whereby WILEX may be granted commercialization rights outside of the United States, including but not limited to Europe, to one of Prometheus' marketed products or receive additional cash payments of up to $20 million.

Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX, commented, "This is the deal we have been looking for, not only in financial, but also in commercial and strategic terms. We are very excited about WILEX'S new partnership with Prometheus since Prometheus has a proven track record in commercializing pharmaceutical and diagnostic products."

"We are very pleased to enter into this partnership with WILEX as we continue to build our oncology franchise," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "RENCAREX® is a great strategic fit with our current oncology portfolio in renal cell carcinoma. There is no product currently approved in the United States for patients who could have recurrence of ccRCC after a kidney resection.  We look forward to working with WILEX to complete the development process and commercialize RENCAREX® in the United States."

About RENCAREX®

RENCAREX® (girentuximab) is a highly specific chimeric monoclonal antibo
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
11. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 2, 2015 The ... global clinical trials review of H2, 2015 provides ... an objective to enhance decision making capabilities of ... report on Keratoconus market clinical trials review spread ... institutes / government organizations and supported with 43 ...
(Date:9/1/2015)... BRISBANE, Australia and Delaware , ... -- Invion Limited (ASX: IVX; "Company" or "Invion"), is pleased ... issue the following securities to an institutional investor in ... for aggregate gross proceeds of approximately A$1.001 million ("Placement") by ... an issue price of $0.014 per share. ...
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
Breaking Medicine Technology:Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... Complete,Genomics Inc., a newly launched, third-generation human ... (ISB) today announced their,partnership to conduct populationwide human ... project, Complete Genomics will use its proprietary,DNA sequencing ... by,ISB. Then, once proof-of-concept has been demonstrated, ISB ...
... 6 Dendreon Corporation (Nasdaq:,DNDN) will host a ... 9:00 AM,ET (6:00 AM PT) to review the ... for Prostate AdenoCarcinoma Treatment, also known as D9902B),clinical ... immunotherapy for the treatment of advanced prostate,cancer., ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:9/2/2015)... ... September 02, 2015 , ... ... content, records and case management solutions and services to both government and commercial ... Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. EDAC ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. Schwartz , ... now certified in “Systema”: a Russian martial art system that is also a philosophy ... Systema , which dates back to the 10th century, is a Russian Martial ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 ... plastic surgeries conducted each year on teenagers, quoting a New York City-area plastic ... Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients ...
(Date:9/1/2015)... ... September 02, 2015 , ... The Journal of Pain Research ... in the USA ”. , As corresponding author Mr Christopher Malone says “Migraine headache ... our study, we endeavoured to better understand how migraine headaches impact the lives of ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2
... France June 04, 2009 The cause of ... after Alzheimer,s disease, is unknown, but in most cases ... risk factors and genetic susceptibility. Laboratory studies in rats ... an animal model of PD and several epidemiological studies ...
... BioTrends Research Group, Inc. announces the release of the baseline ... The survey was completed by U.S. Rheumatologists in May 2009, ... , Once monthly dosing seems to be playing well, according ... of SIMPONI. 84% of the Rheumatologists surveyed report that they ...
... Pa., June 4 Herley Industries, Inc. (Nasdaq: ... Israel, has recently received contracts valued at approximately $4 million ... customer. These are follow-on awards for an existing customer ... to a U.S. aircraft. , , Herley Industries, Inc. ...
... The Cardiovascular Nurse and Technologist Symposium at TCT 2009 ... clinical/administrative strategies for the management of the cardiovascular patient: ... receiving PCI, Revascularization decisions, Management decisions regarding patients with ... charge of your own health WHEN: ...
... uninterrupted supply for customers , , LAKE ZURICH, Ill., ... improving blood collection, safety and availability for patient care, said ... a patent lawsuit brought by Haemonetics Corporation in 2005. ... , , In conjunction with this litigation, ...
... , For Father,s Day, Forget The Usual With A Gift ... Physician Formulated Anti-Wrinkle Moisturizer , , PACIFIC PALISADES, Calif., ... This year, give Dad something he secretly desires but may ... the best for the family hero. Dermagenics Physician-Formulated ...
Cached Medicine News:Health News:Association found between Parkinson's disease and pesticide exposure in French farm workers 2Health News:Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM) 2Health News:Herley's Israeli Subsidiary, GMI Eyal, is Selected to Provide Complex Microwave Switch Assemblies for a U.S. Customer 2Health News:Nurses: Providing angioplasty patient care in and out of the cath lab 2Health News:Fenwal Statement Regarding Patent Litigation 2Health News:SHOW DAD YOU LOVE HIS FACE 2
... Osteopal V is a low viscosity bone ... in vertebroplasty. The bone cement is injected ... purposes. Osteopal V is used for the ... of zirconium dioxide is included in the ...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... a comprehensive platform for standard neurosurgical ... to plan the optimal surgical path ... Combined with unique features such as ... planning tool, Neurosight becomes a very ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with our displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless...
Medicine Products: